Summary The tumour suppressor gene p53 has been found to be mutated or inactivated at high frequency in several common human tumours. We have examined a series of exocrine pancreatic carcinomas for overexpression of mutant forms of p53 by immunohistochemistry with a panel of specific antibodies. We found immunodetectable p53 in 13 of 22 Carcinoma of the exocrine pancreas is the fourth most common cause of death from cancer, leading to 6,000 deaths per year in the UK, and its incidence appears to be rising in Western nations (Williamson, 1988 (Kloppel & Maillet, 1989) .
Carcinoma of the exocrine pancreas is the fourth most common cause of death from cancer, leading to 6,000 deaths per year in the UK, and its incidence appears to be rising in Western nations (Williamson, 1988) . Conventional methods of treatment including surgery, radiotherapy and chemotherapy offer little hope of cure and 5-year survival is reported as less than 1 % with a median survival of 2.8 months (Cancer of the Pancreas Task Force Group 1981) . Little is currently known of its aetiology and pathogenesis, but analysis of the involvement of oncogenes and tumour suppressor genes might enable us to understand better the molecular basis of this cancer and possibly to design new therapeutic strategies .
Among the most striking genetic changes in human pancreatic cancer is the very high frequency point mutation at codon 12 of the Ki-ras oncogene, which affects around 75% of cases (reviewed by Shibata et al., 1990) . Much interest is now focussed on oncogenic events that might cooperate with the Ki-ras oncogene in pancreatic tumorigenesis, and amongst the potential candidates is point mutation of the p53 tumour suppressor gene. Abnormalities of the p53 gene occur at very high frequency in several common human malignancies (see for example Nigro et al., 1989; Takahashi et al., 1989; Baker et al., 1990) , and at least some mutant forms of this gene can cooperate with activated ras oncogenes to produce full cellular transformation in vitro (Hinds et al., 1990) . We have therefore investigated the prevalence of abnormalities of the p53 protein in human pancreatic cancer using a panel of monoclonal and polyclonal antibodies, and confirmed the presence of point mutations in cases of abnormal protein expression using PCR amplification and direct sequencing of cDNA and genomic DNA.
Materials and methods
Tumour samples Our study material comprised 22 human pancreatic cancer samples which had been snap-frozen in liquid nitrogen after surgical resection and subsequently stored at -70°C, and 124 human pancreatic cancer samples in formalin-fixed, paraffin-embedded tissue blocks taken from the pathological archives of Hammersmith Hospital in London and the Academic Hospital Jette in Brussels. The tumours were classified and graded using established histopathological criteria (Kloppel & Maillet, 1989) .
We also studied 13 pancreatic cancer cell lines, some of which we obtained from the American Type Culture Collection (MiaPaCa-2, BxPC-3, CaPan-1, CaPan-2, AsPC-1, PSN- (PBS) . Endogenous peroxidase activity inhibited by incubation of the specimen in 0.1% phenylhydrazine hydrochloride for 5 min at room temperature. The section was then incubated with the primary antibody for 1 h at room temperature (monoclonal antibodies as neat hybridoma supernatant, and the polyclonal antiserum JG8 as a 1/500 dilution in 0.5% bovine serum albumin (BSA) in PBS). The primary antibody was detected using the avidin-biotin complex method (ABC system from Dako Ltd) with diaminobenzidine tetrahydrochloride as the chromogen. room temperature. The section was then incubated for 1 h at room temperature in the polyclonal antiserum CM1 diluted 1 in 800 in 0.5% BSA in PBS. The primary antibody was detected using the ABC system with diaminobenzidine tetrahydrochloride as the chromogen.
Controls Positive controls comprised cell lines previously shown to express p53 genes with activating point mutations and negative controls consisted of replacement of the primary antibody with buffer alone.
Antibodies
Monoclonal antibody PAbl8O1 recognises a denaturationresistant epitope between amino acids 32 and 79 (Banks et al., 1986) , PAb421 recognises a denaturation-resistant epitope located between amino acids 370 and 378 of p53 (WadeEvans & Jenkins, 1985) , and PAb240 recognises a denaturation-resistant epitope located between amino acids 156 and 335 .
JG8 is a high-titre rabbit antiserum raised against a large fragment of murine p53 purified from Escherichia coli containing an expression plasmid , CM1 is a high-titre rabbit antiserum raised against full-length recombinant human p53 (Bartek et al., 1991) .
Immunoprecipitation Cells were lysed in 150 mM NaCl, 50 mM Tris pH 8, 5 mM EDTA, 1% NP40, 1 mM PMSF for 30 min on ice. The cell extract was centrifuged at 100,000 g for 30 min and the pellet was discarded. The extract was preadsorbed with protein G sepharose (Pharmacia), neat hybridoma supernatant was added and the mixture was left overnight at 4°C on a rotating wheel. Protein G beads were added and the incubation was continued for 1 h. The beads were then washed four times in lysis buffer. Denaturing polyacrylamide gel electrophoresis and immunoblotting were performed as described in Harlow & Lane (1988) and Bartek et al. (1990) . Immunoblots were blocked in 0.1% Tween 20 in PBS, probed overnight at 4°C with rabbit anti-p53 serum JG8 diluted 1 in 100 and washed in 0.1% Tween 20 in PBS. The blots were then incubated for 2 h at room temperature in sheep anti-rabbit IgG conjugated to alkaline phosphatase, and bands were visualised after the addition of 5-bromo-4-chloro-3-indoyl phosphate and nitro blue tetrazolium (Promega Inc.).
PCR sequencing p53 cDNA sequencing This was carried out on amplified cDNA from mRNA extracted from the pancreatic cell lines using the oligonucleotide primers and protocols described by Bartek et al. (1990). p53 genomic DNA sequencing from cell lines and frozen tumour tissue This was carried out using the oligonucleotide primers and protocols described by Baker et al. (1990 We have recently described the use of these primers (Wright et al., 1991) which were derived from p53 genomic sequence reported by Chumakov and colleagues (Buchman et al., 1988; Chumakov et al., 1990) , and their location and strategy for use is shown in Figure 1 . DNA for amplification was prepared from paraffin-embedded tissue sections as previously described (Lemoine et al., 1989; Higuchi, 1989) , and symmetric amplification was performed on DNA derived from individual sections using 100 pmol for each primer, 2.5 units of thermostable DNA polymerase (Replinase from Dupont (UK) Ltd), 200LM dNTPs in a total volume of 100 pl buffer (50 mM Tris pH 9, 20 mM ammonium sulphate, 1.5 mM MgCl2). Thirty to 50 cycles of amplification were performed in Cetus Thermal Cycler. Essentially, DNA amplification was performed with a pair of outboard primers around either exon 5, exon 7 or exon 8, and then the amplified fragment purified by excision of the specific band from a 2.5% agarose gel (2% Nusieve, 0.5% Seakem) and recovery of the DNA by electrophoretic concentration (Extraphor Electrophoretic Concentrator, LKB Pharmacia). 10 ng of template DNA was mixed with 20 pmol of relevant inboard primer in a final volume of 8 1I and denatured by heating to 98°C for 7 min, and then 2 il of 5 x Sequenase reaction buffer (United States Biochemical) added. The mixture was then incubated at 37°C for 30 min, then at room temperature for 10 min and finally on ice before proceeding with the standard Sequenase Version 2.0 (United States Biochemical) sequencing protocol using 3"S-dATP.
Results

Nuclear immunoreactivity
Of the 22 primary exocrine pancreatic carcinomas studied by immunohistochemistry in frozen sections, 13 (60%) possessed nuclear immunoreactivity with the JG8 and CM1 polyclonal antisera and of these 11 had immunoreactivity with the mutant-specific monoclonal antibody 240 (PAb240). Not which there was faint cytoplasmic staining without nuclear staining were not scored as positive in this analysis. Seven of the 13 cell lines examined by immunocytochemistry on cells grown on glass slides showed nuclear immunoreactivity with PAb240, PAb421, PAbl8O1 and the polyclonal antiserum CM1 (Table I) ; six of these cell lines also showed reactivity with the antiserum JG8. There was some variation in the preparation of cells positive with each test (Table I) .
The polyclonal antiserum CMI was used to detect p53 immunoreactivity in 124 pancreatic carcinoma cases in routinely-processed paraffin sections. Twenty-eight cases (23%) were positive for nuclear immunoreactivity with this antiserum (Figure 2) . The percentage of positive tumours did not vary significantly with pathological grade (Table II) . In some cases there was definite cytoplasmic staining in addition to convincing nuclear positivity. We did not observe this phenomenon in frozen sections tested with this antibody, and it may represent an effect of fixation and processing. Five 
None detected aPositive signals were graded for proportion of cells with nuclear staining (+ <25%, + + 25-50%, + + + 50-75%, + + + + 75-100%). bPositive signals were graded for intensity (+ to + + + +). PAbl801 and 240. Five cell lines had detectable p53 (Figure 3 ) on immunoprecipitation with antibody PAbl80l, and four of these also showed a band of lesser intensity on immunoprecipitation with the mutant-specific antibody PAb240 (Table I) . (Wright et al., 1991) that can be applied to the low molecular weight genomic DNA obtainable from fixed tissue sections, amplifying the most conserved parts of p53 in exons 5, 7 and 8 representing the 'hot spots' for mutation (Baker et al., 1990) in box II (codon 132-145), box III (codon 171-179), box IV (codon 239-248) and box V (codon 272-286). To examine the relationship between immunoreactivity with the CM1 antiserum in formalin-fixed, paraffin-embedded material and p53 point mutations, we attempted amplification and sequence analysis in eight tumours with positive nuclear staining and four tumours without staining.
We failed to amplify specific DNA in three of the CMlpositive cases and in one of the CM 1-negative cases. We found point mutations in three of the CM 1-positive cases (codon 246 ATG to ATT, methionine to isoleucine; codon 249 AGG to AAG, arginine to leucine; codon 273 CGT to CAT, arginine to histidine), confirmed on both sense and antisense strands. We infer that the mutant gene is hemizygous in each of these cases because the band representing wild type sequence is absent or much weaker than the band for the mutant sequence (Figure 4) . We do not have high molecular weight DNA available for these cases and so are unable to confirm allelic deletions by RFLP analysis of chromosome 17p. Only wild type sequence was present in the CM1-negative cases. In this small series point mutations in the hot spots were therefore restricted to CM1-positive cases, although of course we have not excluded abnormalities in other areas of the p53 gene.
We used direct sequencing of product amplified from genomic DNA and cDNA of each of the cell lines to confirm expression of a mutant p53 gene. Point mutations of the coding sequence in exons 5, 6, 7 and 8 were identified (Figures 5 and 6) in all of the cell lines overexpressing p53 by immunoprecipitation analysis (Panc-1, HPAF, PT45, MiaPaCa-2 and PSN-1). The CaPanl and BxPc3 cell lines were positive by immunocytochemistry but negative by immunoprecipitation analysis, and no mutation in any exon was identified in these lines. Since p53-immunoreactive cells form only a minority population in the BxPc3 cell line it is possible that we could miss a mutation by the direct sequencing technique, particularly if the mutation is heterozygous. The explanation for our failure to identify an activating mutation in the CaPanl cell line is currently obscure, but it is interesting that immunoprecipitation analysis failed to detect high levels of mutant p53 in contrast to the immunocytochemical analysis. None of the cell lines that lacked immunoreactive p53 protein possessed point mutations in any exon.
Discussion
Our results indicate that p53 abormalities occur at high frequency in pancreatic cancer, similar to the frequencies reported in other common human malignancies such as colorectal cancer (Rodrigues et al., 1990; Baker et al., 1990) , breast cancer , lung cancer (Chiba et al., 1990 ) and hepatocellular cancer (Hsu et al., 1991; Bressac et al., 1991) . Using frozen tissue and a panel of anti-p53 antibodies (including the CM 1 polyclonal antiserum) we detected overexpression of mutant p53 protein in 60% of cases of pancreatic cancer. With paraffin sections, using only the CM 1 antiserum, we found a smaller proportion of cases (20-25%) showing nuclear immunoreactivity. This difference in p53 immunoreactivity is probably because the epitope recognised by CM1 antiserum is only partially resistant to formalin fixation. Examination of genomic DNA extracted from representative paraffin sections confirmed that point mutations were present in conserved regions of the p53 gene in those cases showing positive p53 immunoreactivity.
Sequence analysis of those cases expressing high levels of p53 protein also allowed identification of a point mutation in the coding sequence of exons 5, 6 7 or 8 in most cases. The nature of the base change involved showed no special predilection, with G to A transitions, C to T transitions and G to T transversions identified in this series. In non-small cell lung cancer (Chiba et al., 1990 ) and hepatocellular cancers (Hsu et al., 1991; Bressac et al., 1991) there is a very high frequency of G to T transversions, while in most other tumour types there is an excess of G to A transitions (Baker et al., 1989; Bartek et al., 1990; Nigro et al., 1990 relatively weak association with environmental factors such as cigarette smoking, alcohol and coffee drinking have been described (Doll & Peto, 1976; McMahon, 1982) . In contrast, both hepatocellular cancer and non-small cell lung cancer have relatively strong associations with potent environmental carcinogens: hepatocellular cancer with hepatitis B virus and aflatoxins, and lung cancer with cigarette smoking. The molecular basis of pancreatic cancer is now becoming clearer, and a number of independent genetic events have been identified in human tumours . In addition to a very high frequency of Ki-ras activation by point mutation (Shibata et al., 1990) , there is evidence of a autocrine loop involving overexpression of transforming growth factor alpha and the epidermal growth factor receptor (Barton et al., 1991; Lemoine et al., 1991a) . These abnormalities may be linked for there is in vitro evidence that activation of ras oncogenes causes upregulation of TGF alpha expression (Ciardello et al., 1990) . Overexpression (sometimes with amplification) of the c-erbB-2 protooncogene has been described in about 20% of pancreatic cancers ). Now we have demonstrated inactivation of the p53 tumour suppressor gene in a large proportion of cases.
The relative importance and sequence of these genetic events in pancreatic carcinogenesis remains to be determined, although we do know that both overexpression of mutant p53 and point mutation of Ki-ras are found in intraductal carcinoma in situ lesions (this study and Lemoine et al., 1991b) . In vitro, normal human epithelial cells may be partially transformed by activated ras oncogenes alone, but for full malignant transformation an additional genetic event, associated with immortalisation, is necessary (Bums et al., 1991) . This additional genetic event may involve the loss or inactivation of a tumour suppressor gene. In patients with Li-Fraumeni syndrome, characterised by a hereditary predisposition to various tumours including pancreatic cancer, germ-line mutations of the p53 gene have been described (Malkin et al., 1990; Srivastava et al., 1990) . In these patients, p53 abnormalities are clearly the earliest genetic event in tumorigenesis. In sporadic colorectal cancer, however, p53 mutation appears to be a late event and it has been suggested that the order of events is not important, the net result being dependent on the accumulation of genetic abnormalities (Baker et al., 1990; Vogelstein, 1991) . In the pancreas carcinoma in situ and other lesions interpreted as intermediate in the progression to invasive cancer are very rarely reported by pathologists, and so it may be difficult to pinpoint the appearance of p53 in the temporal sequence of this tumour.
